This panel includes hormones that have been implicated in gynecomastia by several studies. Gynecomastia is a benign enlargement of the male breast resulting from a growth of the glandular tissue of the breast. Since it causes anxiety, psychosocial discomfort and fear of breast cancer, early diagnostic evaluation is important, and patients usually seek medical attention. Causes include hormone imbalance and genetic predisposition.

This osteoporosis panel includes:

• Serum total calcium, albumin (to calculate albumin adjusted calcium) and phosphorus as part of a CMP panel to detect conditions associated with hypercalcemia such as primary hyperparathyroidism or hypocalcemia and consequent secondary hyperparathyroidism causing bone loss
• Serum creatinine and estimated glomerular filtration rate (GFR) as part of the CMP panel are useful to detect renal failure which can affect bone health. 
• Serum alkaline phosphatase (ALP) as part of a CMP panel. ALP measurement is useful to detect conditions including Paget's disease, metastatic bone disease and osteomalacia, etc.
• Vitamin D nutrition should be determined by measuring serum 25-hydroxy vitamin D [25(OH)D]. Although there is controversy about the optimum level of 25(OH)D for bone health; while 50 nmol/L is considered acceptable
• Parathyroid Hormone (PTH) measurement would be required if serum calcium is abnormal, to help investigate the cause of the calcium abnormality.
• Ultra-sensitive Estradiol. Low estradiol in men and women has been linked to bone loss.
• Phosphorus. An increased phosphorus with decreased calcium suggests either hypoparathyroidism or renal disease. A decreased phosphorus and an increased calcium suggests hyperparathyroidism or sarcoidosis. When both calcium and phosphorus are decreased diagnostic considerations include malabsorption, vitamin D deficiency and renal tubular acidosis. Increased phosphorus and normal or increased calcium suggests Milk-alkali syndrome or hypervitaminosis D.